Famcyclin Tablets (Famciclovir)

Adult dose

1. Treatment of herpes zoster Adults: Administer famciclovir 250 mg per dose orally 3 times daily for 7 days. It is advisable to start treatment as soon as symptoms appear after infection. 2. Treatment of initial genital herpes infection Adults: Administer this medicine 250 mg per dose orally 3 times daily for 5 days. It is advisable to start treatment as soon as symptoms appear after infection. 3. Treatment of acute recurrent genital herpes infection Adults: Administer this medicine 125 mg per dose orally twice daily for 5 days. It is advisable to start treatment during the prodromal period or as soon as symptoms appear after infection. 4. Suppression of recurrent genital herpes Adults: Administer this medicine 250 mg per dose orally twice daily. Periodically interrupt treatment every 6～12 months to observe whether the natural course of the disease has changed. 5. Patients with renal impairment: Since the clearance of this medicine is reduced in patients with renal impairment, adjust the dose carefully. The dosage for these patients is as follows. 1) Treatment of herpes zoster and initial genital herpes infection: Creatinine clearance (mL/min/1.73㎡) Dose 30～59 250 mg per dose twice daily 10～29 250 mg per dose once daily 2) Treatment of acute recurrent genital herpes infection: Creatinine clearance (mL/min/1.73㎡) Dose 30～59 125 mg per dose twice daily 10～29 125 mg per dose once daily 3) Suppression of recurrent genital herpes infection: Creatinine clearance (mL/min/1.73㎡) Dose 30～59 250 mg per dose twice daily 10～29 125 mg per dose twice daily 4) If only serum creatinine is known, creatinine clearance may be calculated using the following formula. Men: {body weight (kg) × (140-age)}/ {72 × serum creatinine (mg/dL)} Women: 0.85 × the value calculated for men 5) Patients with renal impairment undergoing hemodialysis For patients receiving hemodialysis, it is advisable to administer this medicine every 48 hours, taking the dialysis interval into account. Four hours of hemodialysis reduces the plasma concentration of this medicine by about 75%; therefore, administer this medicine immediately after dialysis. The recommended dose is 250mg for patients with herpes zoster and 125mg for patients with genital herpes. 6. Patients with hepatic impairment: No dose adjustment is required in patients with chronic compensated liver disease. There is insufficient treatment experience in patients with overt chronic decompensated liver disease; therefore, a clear recommended dose has not been established.

This medication should not be used by individuals who are allergic to this medication or its components. Additionally, it contains lactose, so it should not be administered to patients with genetic disorders that inhibit the digestion of lactose. Caution is required when using this medication in patients with impaired kidney function, and dosage adjustments may be necessary as needed. During treatment with this medication, symptoms such as headache or nausea may occur, but they are usually mild. Rarely, there may be a decrease in blood cell counts or occurrences of confusion, hallucinations, palpitations, skin rashes, etc. Caution is warranted in patients with poor kidney function due to the risk of acute kidney failure. This medication does not cure genital herpes completely, and it is important to avoid sexual contact and maintain safe sex to prevent the spread of infection during treatment. If symptoms like dizziness or drowsiness occur, it is advisable to refrain from driving or operating machinery. Patients with mild to moderate liver dysfunction do not require special dosage adjustments, but severely impaired liver function may decrease the efficacy of the medication. This medication has a low potential for drug interactions, but caution should be exercised when used in combination with certain medications like probenecid, as it may increase plasma concentrations and the risk of side effects. Pregnant or breastfeeding women should carefully consider the benefits and risks before using this medication, and it is advisable to avoid use in children as safety has not been established. Generally, elderly patients do not require dosage adjustments, but if kidney function is decreased, dosage adjustments are necessary. In case of overdose, appropriate treatment should be initiated, and drug concentrations may be reduced with dialysis. This medication should be stored in a closed container, away from air and moisture, and kept in a cool, dry place below 30 degrees Celsius, out of reach of children, and it should not be transferred to other containers.

• Headache
• nausea
• thrombocytopenia
• leukopenia
• neutropenia
• dizziness
• confusion
• drowsiness
• hallucinations
• palpitations

This medication is sensitive to air and moisture, so it should be stored in a sealed container. It is also advisable to store it in a cool, dry place below 30 degrees Celsius.

Appearance

White round film-coated tablet

Package unit

21 tablets/PTP [7 tablets/PTP*3]